Fresh, sourced stories worth posting about for biotech & pharma professionals — updated every few hours, with the receipts attached. Not generated guesses.
Your desk is ready
Free to start · no card required · your pick is waiting on the other side.
Niche's weekly rollup — one email, no spam.
The stories refresh every few hours from live news and primary sources. Each carries the publisher and the date it was published — so you can see exactly how current it is.
Real reporting and primary filings — every story links its sources. Nothing here is a generated guess; the angle is identified and the receipts are attached.
Yes. These are starting points for your own posts. Draft one and Niche writes it in your voice, platform-native, ready to publish.
Several commentary pieces discuss broader biopharma dealmaking, M&A, cross-border valuation, China licensing costs, radiopharma and GLP-1 supply-chain consolidation, and emerging pharma partnering trends. Together they reflect the strategic backdrop for licensing and acquisition activity across the sector.
Draft a post from this →A set of NIH RePORTER awards covers diverse academic research programs including Alzheimer’s disease, speech imaging in aphasia, deep brain stimulation for tremor, HIV immunity, uterine fibroids, oral cancer microbiome work, and related core infrastructure grants. These are early-stage scientific signals rather than company events.
Draft a post from this →Disc Medicine reported Q2 2026 results and business update highlighting a completed FDA Type A meeting on bitopertin, with alignment that the Phase 3 APOLLO study could support a CRL response if successful. This is the clearest near-term clinical/regulatory catalyst in the set.
Draft a post from this →MapLight Therapeutics reported that its Phase 2 ZEPHYR trial of ML-007C-MA met the PANSS primary endpoint and showed cognitive gains, with tolerability details also highlighted. This is a strong clinical-validation story for a CNS biotech asset.
Draft a post from this →Invivyd received a Nasdaq deficiency letter over the minimum bid price requirement, adding listing pressure to an already challenged clinical-stage company. This is a market-moving capital markets and compliance event.
Draft a post from this →